Free Trial

Arbutus Biopharma (ABUS) News Today

→ AI's Next Magnificent Seven (From The Oxford Club) (Ad)
Free ABUS Stock Alerts
$3.20
-0.14 (-4.19%)
(As of 06/7/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends
June 7 at 5:02 AM | americanbankingnews.com
HC Wainwright Reiterates "Buy" Rating for Arbutus Biopharma (NASDAQ:ABUS)
June 6 at 12:51 PM | marketbeat.com
Arbutus Biopharma (NASDAQ:ABUS) Trading Down 3%
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 3%
June 6 at 11:15 AM | globenewswire.com
Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
June 6 at 8:13 AM | marketbeat.com
Arbutus Biopharma's (ABUS) Buy Rating Reiterated at HC Wainwright
HC Wainwright reissued a "buy" rating and issued a $5.00 target price on shares of Arbutus Biopharma in a research note on Thursday.
June 6 at 4:22 AM | americanbankingnews.com
Arbutus Biopharma (NASDAQ:ABUS) Given "Buy" Rating at Chardan Capital
June 5, 2024 | marketbeat.com
Arbutus Biopharma's (ABUS) Buy Rating Reiterated at Chardan Capital
Chardan Capital reiterated a "buy" rating and issued a $4.00 price objective on shares of Arbutus Biopharma in a research note on Wednesday.
June 5, 2024 | marketbeat.com
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Up 5.7%
Arbutus Biopharma (NASDAQ:ABUS) Trading Up 5.7%
June 5, 2024 | globenewswire.com
Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
June 4, 2024 | marketbeat.com
Arbutus Biopharma (NASDAQ:ABUS) Hits New 1-Year High at $3.44
Arbutus Biopharma (NASDAQ:ABUS) Sets New 52-Week High at $3.44
June 4, 2024 | americanbankingnews.com
Short Interest in Arbutus Biopharma Co. (NASDAQ:ABUS) Decreases By 8.1%
June 3, 2024 | globenewswire.com
Arbutus Distributors Ltd. News Release
June 2, 2024 | marketbeat.com
Arbutus Biopharma Co. (NASDAQ:ABUS) Sees Large Decline in Short Interest
Arbutus Biopharma Co. (NASDAQ:ABUS - Get Free Report) was the recipient of a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 5,340,000 shares, a drop of 8.1% from the April 30th total of 5,810,000 shares. Based on an average daily volume of 1,150,000 shares, the days-to-cover ratio is presently 4.6 days.
May 31, 2024 | americanbankingnews.com
Arbutus Biopharma (NASDAQ:ABUS) Shares Pass Above Two Hundred Day Moving Average of $2.57
May 31, 2024 | marketbeat.com
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Passes Above 200 Day Moving Average of $2.57
Arbutus Biopharma (NASDAQ:ABUS) Share Price Passes Above 200 Day Moving Average of $2.57
May 29, 2024 | globenewswire.com
Arbutus to Participate in Jefferies Global Healthcare Conference
May 23, 2024 | marketbeat.com
Arbutus Biopharma (NASDAQ:ABUS) Shares Down 4.7%
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 4.7%
May 22, 2024 | marketbeat.com
Arbutus Biopharma (NASDAQ:ABUS) Reaches New 52-Week High at $3.29
Arbutus Biopharma (NASDAQ:ABUS) Reaches New 12-Month High at $3.29
May 22, 2024 | globenewswire.com
Arbutus to Present Imdusiran Data at EASL Congress 2024
May 21, 2024 | marketbeat.com
Arbutus Biopharma (NASDAQ:ABUS) Trading Up 3.6%
Arbutus Biopharma (NASDAQ:ABUS) Trading Up 3.6%
May 17, 2024 | morningstar.com
Arbutus Biopharma Corp ABUS
May 17, 2024 | bizjournals.com
Mike Sofia, who discovered cure for hepatitis C, set to retire from Arbutus Biopharma
May 17, 2024 | finance.yahoo.com
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program
May 17, 2024 | finance.yahoo.com
Update: Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program
May 17, 2024 | businesswire.com
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
May 10, 2024 | msn.com
Arbutus Biopharma to Engage Investors at Upcoming New York Conferences
May 7, 2024 | globenewswire.com
Arbutus to Participate in Two Upcoming Investor Conferences
May 3, 2024 | markets.businessinsider.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arbutus Biopharma (ABUS), Neurocrine (NBIX) and Bausch Health Companies (BHC)
May 3, 2024 | finance.yahoo.com
Arbutus Biopharma Corp (ABUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
May 3, 2024 | finance.yahoo.com
Arbutus Biopharma First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
May 3, 2024 | finance.yahoo.com
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript
May 3, 2024 | marketbeat.com
Arbutus Biopharma's (ABUS) Buy Rating Reaffirmed at Chardan Capital
Chardan Capital reissued a "buy" rating and issued a $4.00 price target on shares of Arbutus Biopharma in a research note on Friday.
May 3, 2024 | msn.com
Arbutus Biopharma Makes Headway in Hepatitis B Treatment and Defends Intellectual Property Amidst Q1 2024 Financial Release
May 2, 2024 | finance.yahoo.com
Arbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial Review
May 2, 2024 | investorplace.com
ABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024
May 2, 2024 | washingtonpost.com
Arbutus: Q1 Earnings Snapshot
May 2, 2024 | globenewswire.com
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 2, 2024 | globenewswire.com
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
May 1, 2024 | markets.businessinsider.com
Arbutus Biopharma earnings: here's what to expect
May 1, 2024 | msn.com
Arbutus Biopharma Q1 2024 Earnings Preview
April 30, 2024 | money.usnews.com
Arbutus Biopharma Corp
April 21, 2024 | msn.com
Arbutus Biopharma Sets Date for Q1 2024 Financial Results
April 18, 2024 | globenewswire.com
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
April 10, 2024 | seekingalpha.com
Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains
April 4, 2024 | msn.com
Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge
April 4, 2024 | marketbeat.com
Arbutus Biopharma (NASDAQ:ABUS) Sees Unusually-High Trading Volume
Arbutus Biopharma (NASDAQ:ABUS) Sees Large Volume Increase
April 4, 2024 | markets.businessinsider.com
Arbutus Biopharma Reports Claim Construction Ruling In Patent Infringement Lawsuit Against Moderna
April 4, 2024 | marketbeat.com
Arbutus Biopharma (NASDAQ:ABUS) Earns "Market Outperform" Rating from JMP Securities
JMP Securities reiterated a "market outperform" rating and issued a $4.00 price objective on shares of Arbutus Biopharma in a research note on Thursday.
April 4, 2024 | globenewswire.com
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
April 3, 2024 | marketbeat.com
Arbutus Biopharma (NASDAQ:ABUS) Hits New 52-Week High at $3.25
Arbutus Biopharma (NASDAQ:ABUS) Reaches New 52-Week High at $3.25
April 3, 2024 | seekingalpha.com
Arbutus Biopharma jumps after claim construction order in patent fight with Moderna
Get Arbutus Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.

Biden Nomination CANCELED? (Ad)

And I believe when they do take the oath of office, their fingers will be crossed… and America will descend into chaos.

Click here now to see my urgent election warning.

ABUS Media Mentions By Week

ABUS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ABUS
News Sentiment
▼
0.28

0.75
▲
Average
Medical
News Sentiment

ABUS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ABUS Articles
This Week
▼
13

2
▲
ABUS Articles
Average Week

Get Arbutus Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:ABUS) was last updated on 6/9/2024 by MarketBeat.com Staff

From Our Partners
Write this ticker symbol down…
A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...
StocksToTrade | Sponsored
Breaking - The US Gov. Seized CITGO
Do you want an investment that can double or triple your money in the next three months? The US Court is cu...
Augury Research | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored
AI's Next Magnificent Seven
The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.
The Oxford Club | Sponsored
Urgent alert: open this for a huge profit potential
This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo...
Timothy Sykes | Sponsored
Who are Nvidia’s Silent Partners?
Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.
Weiss Ratings | Sponsored